1.DeFilipp Z, Navarro-Alvarez N, Li S, Andrews AR, Johnson A, Chen Y-B, Ho VT, Ritz J, Spitzer TR, Huang CA. Elevated plasma galectin-3 concentrations in recipients of allogeneic hematopoietic cell transplantation. Clin Hematol International. 2019; 1:201-204.
2.Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Ritz J, Soiffer RJ, Koreth J. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft versus host disease. Blood Adv 2019; 3:969-979.
3.Whangbo JS, Kim HT, Nikiforow S, Koreth J, Alho AC, Falahee B, Kim S, Dusenbury K, Fields MJ, Reynolds CG, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv 2019; 3:984-994.
4.Paul J, Nakasone H, Sahaf B, Wu F, Wang K, Ho V, Wu J, Kim H, Blazar BR, Ritz J, Howard A, Cutler C, Miklos D. A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica 2019; 104:e314-e317.
5.Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 2019; 134:22-29.
6.Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL. Recurrent genetic HLA loss In AML relapsed after matched allogeneic hematopoietic cell transplant. Blood Adv 2019; 3:2199-2204.
7.Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen K, Marty FM, Tan CS, Ritz J, Politikos I, Boussiotis V. Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clin Immunol 2019; 207:18-39.
8.Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Politikos I, Boussiotis VA. Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplant 2019; DOI: 10.1038/s41409-019-0707-x
9.Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA*, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host-disease in adults and children. Blood Adv 2019; 3:2550-2561.
10.DeFilipp Z, Navarro-Alvarez N, Li S, Andrews AR, Johnson A, Chen Y-B, Ho VT, Ritz J, Spitzer TR, Huang CA. Elevated plasma galectin-3 concentrations in recipients of allogeneic hematopoietic cell transplantation. Clin Hematol International. 2019; 1:201-204.
11.DeFilipp Z, Li S, Avigan D, Armand P,. Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, Spitzer TR, Chen Y-B, Soiffer RJ, Antin JH, Ballen KK Cutler CS. A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body radiation. Bone Marrow Transplant. 2020; 55:804-810.
12.Espada E, Cheng MP, Kim HT, Woolley AE, Avigan JI, Forcade E, Soares MVD, Lacerda JF, Nikiforow S, Gooptu M, Romee R, Alyea EP, Armand P, Cutler CS, Ho VT, Koreth J, Antin JH, Soiffer RJ, Marty FM, Ritz J. BK virus-specific T cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv 2020; 4:1881-1893.
13.Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, Adamia S, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020; 24(5):2968-2980.
14.Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen Y-B, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood 2020; 135:2182-2191.
15.Mouhieddine TH, Park J, Redd R, Sperling AS, Leventhal M, Gibson CJ, Manier S, Nassar AH, Capelletti M, Huynh D, Bustoros MW, Sklavenitis-Pistofidis R, Sabrin T, Hornburg K, Dumke H, Itani MM, Boehner CJ, Lui CJ, AlDubayan SH, Reardon B, Van Allen EM, Keats JJ, Stewart C, Mehr S, Auclair D, Schlossman RL, Munshi NC, Anderson KC, Steensma DP, Laubach JP, Richardson PG, Ritz J, Ebert BL, Soiffer RJ, Trippa L, Getz G, Neuberg DS, Ghobrial IM. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Comm 2020; 11:2996.
16.Divito SJ, Aasebø AT, Matos TR, Hsieh P-T, Collin M, Elco CP, O’Malley JT, Bækkevold ES, Reims H, Gedde-Dahl T, Hagerstrom M, Hilaire J, Lian JW, Milford EL, Pinkus GS, Ho VT, Soiffer RJ, Kim HT, Mihm MC, Ritz J, Guleria I, Cutler CS, Clark RA, Jahnsen FL, Kupper TS. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. J Clin Invest 2020; 130:4624-4636.
17.Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Armand P, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, Ritz J, Brown JR. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv 2020; 4:4113-4123.
18.Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz GA, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to graft-versus-leukemia effect. Sci Transl Med 2020; 12,eabb7661.
19.Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen P-H, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen Y-B, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol 2020; 38:3095-3106.
20.Leick M, Gittelman RM, Yusko E, Sanders C, Robins H, DeFilipp Z, Nikiforow S, Ritz J, Chen Y-B. T-cell clonal dynamics determined by high resolution TCR-β sequencing in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2020; 26:1567-1574.
21.Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, Baumeister SHC. Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Frontiers Immunol 2020; Dec 15;11:580328.
22.Choi I-K, Wang Z, Ke Q, Hong M, Paul DW, Fernandes SM, Hu Z, Stevens J, Guleria I, Kim H-J, Cantor H, Wucherpfennig KW, Brown JR, Ritz J, Zhang B. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 2021;590:157-162.
23.Rambaldi B, Kim HT, Reynolds C, Rai SC, Kubo T, Buon L, Gooptu M, Koreth J, Cutler CS, Nikiforow S, Ho VT, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, Ritz J, Romee R. Impaired T and NK cell reconstitution after haploidentical HCT with post-transplant cyclophosphamide. Blood Adv 2021; 5:352-364.
24.Matos TR, Hirakawa M, Liu H, Alho AC, Neleman L, Graca L, Ritz J. Maturation and phenotypic diversity of human CD4+ regulatory T cells from birth to adulthood and after allogeneic stem cell transplantation. Frontiers Immunol 2021; Jan 18;11:570550.
25.Raundhal M, Ghosh S, Myers SA, Cuoco MS, Singer M, Carr SA, Waikar SS, Bonventre JV, Ritz J, Stone RM, Steensma DP, Regev A, Glimcher LH. Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nature Immunol 2021; 22:520-529.